据港交所文件：上海君赛生物股份有限公司-B向港交所提交上市申请书，独家保荐人为中信证券。

Shares plunged today. The company said the decline reflected multiple factors and that a previously disclosed executive share-sell plan has not yet been implemented; timing and price of any sales are at the discretion of the individuals. Performance and order trends await the upcoming half-year report. In an investor-relations note the company said it will pursue higher asset-use efficiency in 2026 and aims to stabilise and sustain business growth while improving operating efficiency and long-term viability.

FITCH says inf and interest-rate headwinds are weighing on the US mid-year credit outlook.